A DNA vaccine to prevent transmission of human malaria

预防人类疟疾传播的 DNA 疫苗

基本信息

  • 批准号:
    7893555
  • 负责人:
  • 金额:
    $ 31.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-13 至 2012-09-12
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The current application is submitted in response to the notice number NOT-OD-058 entitled "Enabling RPGs to Leverage NCRR Center and Centers-like Programs". The research focus of the parent grant RO1AI0470889 is to develop a vaccine targeting human malaria. Transmission blocking vaccines (TBVs) against malaria are intended to induce immunity against the stages of the parasite that infect mosquitoes so that malaria transmission is reduced or halted. The target antigens include proteins synthesized in the gametocytes (pre-fertilization antigens, in P. falciparum: Pfs230 and Pfs48/45) and in the zygotes-ookinetes (post-fertilization antigens, in P. falciparum: Pfs25 and Pfs28) and the epitopes recognized by transmission blocking antibodies are cysteine-rich reduction-sensitive conformational in nature. Studies proposed in the parent grant were aimed at (1) identifying immunologically relevant domains in the pre- fertilization antigens, (2) optimizing the combination of pre- and post-fertilization antigens by vaccine formulation in cationic lipids and vaccine delivery by in vivo electroporation, (3) evaluating a candidate DNA vaccine by in vivo electroporation in nonhuman primates (Macaca mulatta) and testing the concept that immunity against pre-fertilization antigens can be maintained by boosting during natural infection using an Aotus model for P. falciparum infection. Moreover, the development of Pfs25 transgenic P. berghei will provide an approach for in vivo evaluation of human malaria TBV based on Pfs25, as compared to a standard in vitro membrane feeding assay. Since most vaccines go through immunogenicity and functional evaluation (wherever biologically feasible) in nonhuman primates, it is now proposed to revise the scope of the parent grant to develop transgenic nonhuman malaria parasite expressing Pfs25 which would then facilitate optimization and evaluation of Pfs25-based TBV. PUBLIC HEALTH RELEVANCE: Malaria causes more than 300 million infections worldwide. Our long term goal is to develop a vaccine to stop transmission of malaria. Research proposed in this application, in particular, will result in the development of a nonhuman primate model to test such human malaria transmission blocking vaccines.
描述(由申请人提供):当前申请是根据编号为no - od -058的题为“使rpg能够利用NCRR中心和类似中心的项目”的通知提交的。母基金RO1AI0470889的研究重点是开发针对人类疟疾的疫苗。疟疾传播阻断疫苗(TBVs)旨在诱导对感染蚊子的寄生虫各阶段产生免疫力,从而减少或阻止疟疾传播。靶抗原包括配子体中合成的蛋白(受精前抗原,恶性疟原虫中:Pfs230和Pfs48/45)和受精卵-卵母细胞中合成的蛋白(受精后抗原,恶性疟原虫中:Pfs25和Pfs28),传播阻断抗体识别的表位本质上是富含半胱氨酸的还原敏感构象。在母体资助中提出的研究旨在(1)鉴定受精前抗原的免疫学相关结构域,(2)通过在阳离子脂质中配制疫苗和通过体内电穿孔给药来优化受精前和受精后抗原的组合。(3)在非人灵长类动物(猕猴)体内电穿孔法评估候选DNA疫苗,并利用Aotus恶性疟原虫感染模型,在自然感染期间增强对受精前抗原的免疫,以验证这一概念。此外,与标准的体外膜饲养试验相比,转基因Pfs25的开发将为基于Pfs25的人疟疾TBV的体内评估提供一种方法。由于大多数疫苗在非人灵长类动物中都经过免疫原性和功能评估(只要生物学上可行),因此现在建议修改亲本资助的范围,以开发表达Pfs25的转基因非人疟疾寄生虫,从而促进基于Pfs25的TBV的优化和评估。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nirbhay Kumar其他文献

Nirbhay Kumar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nirbhay Kumar', 18)}}的其他基金

Combination Vaccines to Interrupt Malaria Transmission
阻断疟疾传播的联合疫苗
  • 批准号:
    9750618
  • 财政年份:
    2017
  • 资助金额:
    $ 31.88万
  • 项目类别:
Combination Vaccines to Interrupt Malaria Transmission
阻断疟疾传播的联合疫苗
  • 批准号:
    9381629
  • 财政年份:
    2017
  • 资助金额:
    $ 31.88万
  • 项目类别:
Identification of Transmission blocking epitopes on P. vivax 48/45 protein
间日疟原虫 48/45 蛋白上传播阻断表位的鉴定
  • 批准号:
    8986156
  • 财政年份:
    2014
  • 资助金额:
    $ 31.88万
  • 项目类别:
Rational Approach to Optimize Immune Potency of DNA Vaccines
优化 DNA 疫苗免疫效力的合理方法
  • 批准号:
    8676649
  • 财政年份:
    2013
  • 资助金额:
    $ 31.88万
  • 项目类别:
Rational Approach to Optimize Immune Potency of DNA Vaccines
优化 DNA 疫苗免疫效力的合理方法
  • 批准号:
    8535062
  • 财政年份:
    2013
  • 资助金额:
    $ 31.88万
  • 项目类别:
Malaria Vaccine Adjuvant Immunogenicity and Safety
疟疾疫苗佐剂的免疫原性和安全性
  • 批准号:
    8351069
  • 财政年份:
    2012
  • 资助金额:
    $ 31.88万
  • 项目类别:
Malaria Vaccine Adjuvant Immunogenicity and Safety
疟疾疫苗佐剂的免疫原性和安全性
  • 批准号:
    8515930
  • 财政年份:
    2012
  • 资助金额:
    $ 31.88万
  • 项目类别:
Plasmodium Recombination of Machinery
机械的疟原虫重组
  • 批准号:
    7834524
  • 财政年份:
    2009
  • 资助金额:
    $ 31.88万
  • 项目类别:
Plasmodium Recombination of Machinery
机械的疟原虫重组
  • 批准号:
    7630336
  • 财政年份:
    2008
  • 资助金额:
    $ 31.88万
  • 项目类别:
MALARIA RESEARCH AND TRAINING PROGRAM IN ZIMBABWE
津巴布韦疟疾研究和培训项目
  • 批准号:
    6395018
  • 财政年份:
    2000
  • 资助金额:
    $ 31.88万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 31.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了